Generation Bio Co. (NASDAQ:GBIO) Receives Average Rating of “Hold” from Analysts

Generation Bio Co. (NASDAQ:GBIO) has been given a consensus recommendation of “Hold” by the six research firms that are currently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $8.00.

A number of research analysts have recently issued reports on the stock. Wedbush restated an “outperform” rating and issued a $5.00 price target on shares of Generation Bio in a research report on Thursday, March 7th. Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of Generation Bio in a research note on Wednesday, April 10th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Generation Bio during the third quarter valued at approximately $51,000. Panagora Asset Management Inc. bought a new position in Generation Bio in the 4th quarter worth approximately $49,000. Kestra Private Wealth Services LLC acquired a new stake in Generation Bio in the 4th quarter valued at approximately $50,000. Weiss Asset Management LP bought a new stake in Generation Bio during the 4th quarter valued at $135,000. Finally, Los Angeles Capital Management LLC boosted its position in Generation Bio by 38.4% during the 1st quarter. Los Angeles Capital Management LLC now owns 381,661 shares of the company’s stock worth $1,553,000 after acquiring an additional 105,827 shares during the period. Institutional investors own 95.22% of the company’s stock.

Generation Bio Stock Performance

Shares of Generation Bio stock opened at $3.01 on Friday. The firm has a market cap of $200.10 million, a PE ratio of -1.54 and a beta of 2.79. Generation Bio has a 1 year low of $0.86 and a 1 year high of $6.98. The firm’s 50-day simple moving average is $3.13 and its 200-day simple moving average is $2.21.

Generation Bio (NASDAQ:GBIO) last released its earnings results on Wednesday, March 6th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.12). The business had revenue of $2.88 million during the quarter, compared to the consensus estimate of $3.05 million. On average, equities analysts predict that Generation Bio will post -1.34 earnings per share for the current year.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.